SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 211 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 3.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,626,988 | -15.7% | 59,013 | -8.1% | 0.00% | 0.0% |
| Q2 2023 | $1,929,822 | -19.2% | 64,199 | -2.6% | 0.00% | -25.0% |
| Q1 2023 | $2,389,187 | +0.9% | 65,945 | -0.6% | 0.00% | 0.0% |
| Q4 2022 | $2,366,812 | +7.0% | 66,353 | +1.6% | 0.00% | 0.0% |
| Q3 2022 | $2,211,000 | +14.8% | 65,313 | -1.9% | 0.00% | +33.3% |
| Q2 2022 | $1,926,000 | -10.3% | 66,590 | +0.2% | 0.00% | 0.0% |
| Q1 2022 | $2,147,000 | +2.4% | 66,433 | -7.6% | 0.00% | +50.0% |
| Q4 2021 | $2,096,000 | +12.5% | 71,871 | +2.9% | 0.00% | 0.0% |
| Q3 2021 | $1,863,000 | -10.8% | 69,837 | +3.0% | 0.00% | -33.3% |
| Q2 2021 | $2,088,000 | +8.4% | 67,799 | -7.8% | 0.00% | 0.0% |
| Q1 2021 | $1,926,000 | +3.5% | 73,562 | -0.5% | 0.00% | 0.0% |
| Q4 2020 | $1,860,000 | +21.3% | 73,940 | +0.5% | 0.00% | +50.0% |
| Q3 2020 | $1,533,000 | -12.2% | 73,553 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $1,747,000 | +30.4% | 73,553 | -1.2% | 0.00% | 0.0% |
| Q1 2020 | $1,340,000 | -25.0% | 74,479 | -1.1% | 0.00% | 0.0% |
| Q4 2019 | $1,787,000 | -15.4% | 75,320 | -2.0% | 0.00% | -25.0% |
| Q3 2019 | $2,112,000 | -15.9% | 76,841 | +1.2% | 0.00% | -20.0% |
| Q2 2019 | $2,512,000 | -4.4% | 75,924 | +1.3% | 0.01% | 0.0% |
| Q1 2019 | $2,627,000 | +3.2% | 74,977 | -2.2% | 0.01% | -16.7% |
| Q4 2018 | $2,546,000 | -32.5% | 76,644 | +2.3% | 0.01% | -14.3% |
| Q3 2018 | $3,772,000 | -15.9% | 74,915 | -0.0% | 0.01% | -22.2% |
| Q2 2018 | $4,485,000 | +33.1% | 74,942 | +1.9% | 0.01% | +28.6% |
| Q1 2018 | $3,369,000 | +11.0% | 73,563 | -3.4% | 0.01% | +16.7% |
| Q4 2017 | $3,034,000 | -0.0% | 76,142 | +0.3% | 0.01% | -14.3% |
| Q3 2017 | $3,035,000 | -16.1% | 75,880 | -9.6% | 0.01% | -12.5% |
| Q2 2017 | $3,619,000 | +25.2% | 83,974 | -9.1% | 0.01% | +33.3% |
| Q1 2017 | $2,891,000 | +18.3% | 92,380 | -4.5% | 0.01% | +20.0% |
| Q4 2016 | $2,444,000 | -0.4% | 96,780 | -2.5% | 0.01% | 0.0% |
| Q3 2016 | $2,455,000 | +22.5% | 99,280 | +0.9% | 0.01% | +25.0% |
| Q2 2016 | $2,004,000 | +80.5% | 98,380 | +35.2% | 0.00% | +100.0% |
| Q1 2016 | $1,110,000 | -80.6% | 72,783 | -82.9% | 0.00% | -85.7% |
| Q4 2015 | $5,708,000 | +550.9% | 424,712 | +579.2% | 0.01% | +600.0% |
| Q3 2015 | $877,000 | -74.7% | 62,534 | -69.4% | 0.00% | -75.0% |
| Q2 2015 | $3,472,000 | +436.6% | 204,483 | +282.3% | 0.01% | +300.0% |
| Q1 2015 | $647,000 | +43.5% | 53,483 | -1.5% | 0.00% | +100.0% |
| Q4 2014 | $451,000 | -4.0% | 54,283 | +0.4% | 0.00% | 0.0% |
| Q3 2014 | $470,000 | -19.7% | 54,052 | +1.1% | 0.00% | 0.0% |
| Q2 2014 | $585,000 | +77.8% | 53,445 | +45.4% | 0.00% | 0.0% |
| Q1 2014 | $329,000 | +48.2% | 36,745 | +24.8% | 0.00% | 0.0% |
| Q4 2013 | $222,000 | +13.8% | 29,445 | +10.5% | 0.00% | 0.0% |
| Q3 2013 | $195,000 | +16.8% | 26,645 | +2.7% | 0.00% | 0.0% |
| Q2 2013 | $167,000 | +297.6% | 25,945 | +246.8% | 0.00% | – |
| Q1 2013 | $42,000 | – | 7,482 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |